A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Participants must have metastatic colorectal or pancreatic cancer

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

- Ability to swallow pills or capsules

- All participants will be required to undergo mandatory pre and on-treatment biopsies

- Adequate marrow function

- Adequate other organ functions

- Ability to comply with study visits, treatment, procedures, PK and PD sample
collection, and required study follow-up

Exclusion Criteria:

- Histology other than adenocarcinoma (neuroendocrine or acinar cell)

- Suspected, known, or progressive CNS metastases (Imaging required only if participants
are symptomatic)

- Participants with active, known or suspected autoimmune disease

- Participants with a condition requiring systemic treatment with either corticosteroids
(> 10 mg daily prednisone equivalents) or other immunosuppressive medications within
14 days of study treatment administration

- Interstitial lung disease that is symptomatic or may interfere with the detection or
management of suspected treatment-related pulmonary toxicity

- Prior treatment with CCR2 and/or CCR5 inhibitors, PD-1, PD(L)-1 or CTLA-4 antibodies

- History of allergy to study treatments or any of its components of the study arm that
participant is enrolling

Other protocol defined inclusion/exclusion criteria could apply